eNOS Pharmaceuticals

eNOS Pharmaceuticals was a biotechnology company focused on developing therapies to treat cardiovascular diseases by targeting the endothelial nitric oxide synthase (eNOS) pathway. The company's core technology involved enhancing the production of nitric oxide to prevent restenosis and promote vascular health. Its research centered on gene therapy and pharmacological approaches to restore endothelial function in damaged blood vessels. Founded on research from New York Medical College and Yale University, the company aimed to integrate biological healing with medical device technology. In 2005, the company was acquired by Cook Medical to incorporate its vascular healing technologies into Cook's interventional medical device portfolio.